Nature Cancer, Journal Year: 2023, Volume and Issue: 4(9), P. 1217 - 1219
Published: July 27, 2023
Language: Английский
Cell, Journal Year: 2023, Volume and Issue: 186(21), P. 4546 - 4566.e27
Published: Sept. 27, 2023
Neutrophils are abundant immune cells in the circulation and frequently infiltrate tumors substantial numbers. However, their precise functions different cancer types remain incompletely understood, including brain microenvironment. We therefore investigated neutrophils tumor tissue of glioma metastasis patients, with matched peripheral blood, herein describe first in-depth analysis neutrophil phenotypes these tissues. Orthogonal profiling strategies humans mice revealed that tumor-associated (TANs) differ significantly from blood have a prolonged lifespan immune-suppressive pro-angiogenic capacity. TANs exhibit distinct inflammatory signature, driven by combination soluble mediators necrosis factor alpha (TNF-ɑ) Ceruloplasmin, which is more pronounced versus glioma. Myeloid cells, macrophages, emerge at core this network pro-inflammatory mediators, supporting concept critical myeloid niche regulating overall suppression human tumors.
Language: Английский
Citations
78
Cancer Cell, Journal Year: 2024, Volume and Issue: 42(3), P. 378 - 395.e10
Published: Jan. 21, 2024
Brain metastasis (BrM) is a common malignancy, predominantly originating from lung, melanoma, and breast cancers. The vasculature key component of the BrM tumor microenvironment with critical roles in regulating metastatic seeding progression. However, heterogeneity major vascular components, namely endothelial mural cells, still poorly understood. We perform single-cell bulk RNA-sequencing sorted cell types detect multiple subtypes enriched specifically compared to non-tumor brain, including previously unrecognized immune regulatory subtypes. integrate human data mouse models, creating platform interrogate targets for treatment BrM. find that CD276 checkpoint molecule significantly upregulated vasculature, anti-CD276 blocking antibodies prolonged survival preclinical trials. This study provides important insights into complex interactions between cancer translational relevance designing therapeutic interventions.
Language: Английский
Citations
28
Nature Immunology, Journal Year: 2024, Volume and Issue: 25(10), P. 1845 - 1857
Published: Aug. 28, 2024
Language: Английский
Citations
11
npj Precision Oncology, Journal Year: 2025, Volume and Issue: 9(1)
Published: Jan. 29, 2025
Brain metastasis leads to poor outcomes and CNS injury, significantly reducing quality of life survival rates. Advances in understanding the tumor immune microenvironment have revealed promise immunotherapies, which, alongside surgery, chemotherapy, radiation, offer improved for some patients. However, resistance immunotherapy remains a critical challenge. This review explores landscape brain metastases, current therapies, clinical trials, need personalized, biomarker-driven approaches optimize outcomes.
Language: Английский
Citations
1
Immunity, Journal Year: 2025, Volume and Issue: unknown
Published: March 1, 2025
Language: Английский
Citations
1
Nature Medicine, Journal Year: 2024, Volume and Issue: 30(10), P. 2947 - 2956
Published: July 31, 2024
The ecosystem of brain tumors is considered immunosuppressed, but our current knowledge may be incomplete. Here we analyzed clinical cell and tissue specimens derived from patients presenting with glioblastoma or nonmalignant intracranial disease to report that the cranial bone (CB) marrow, in juxtaposition treatment-naive tumors, harbors active lymphoid populations at time initial diagnosis. Clinical anatomical imaging, single-cell molecular immune profiling quantification tumor reactivity identified CD8
Language: Английский
Citations
8
International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(4), P. 2044 - 2044
Published: Feb. 7, 2024
Brain metastases represent a significant clinical challenge in the treatment of non-small-cell lung cancer (NSCLC), often leading to severe decline patient prognosis and survival. Recent advances imaging systemic treatments have increased detection rates brain metastases, yet outcomes remain dismal due complexity metastatic tumor microenvironment (TME) lack specific biomarkers for early targeted therapy. The intricate interplay between NSCLC cells surrounding TME is pivotal, influencing progression, immune evasion, response This underscores necessity deeper understanding molecular underpinnings microenvironment, identification actionable that can inform multimodal approaches. goal this review synthesize current insights into elucidate mechanisms metastases. Furthermore, we will explore promising horizon emerging biomarkers, both tissue- liquid-based, hold potential radically transform strategies enhancement outcomes.
Language: Английский
Citations
7
Cancer Cell, Journal Year: 2024, Volume and Issue: unknown
Published: Sept. 1, 2024
Language: Английский
Citations
7
Nature Communications, Journal Year: 2023, Volume and Issue: 14(1)
Published: Sept. 4, 2023
Flow cytometry (FCM) can investigate dozens of parameters from millions cells and hundreds specimens in a short time at reasonable cost, but the amount data that is generated considerable. Computational approaches are useful to identify novel subpopulations molecular biomarkers, generally require deep expertize bioinformatics use different platforms. To overcome these limitations, we introduce CRUSTY, an interactive, user-friendly webtool incorporating most popular algorithms for FCM analysis, capable visualizing graphical tabular results automatically generating publication-quality figures within minutes. CRUSTY also hosts interactive interface exploration real time. Thus, enables large number users mine complex datasets reduce required interpretation. accessible https://crusty.humanitas.it/ .
Language: Английский
Citations
15
Cancers, Journal Year: 2024, Volume and Issue: 16(3), P. 603 - 603
Published: Jan. 31, 2024
Glioblastoma (GBM) is the most aggressive and lethal primary brain tumor, bearing a survival estimate below 10% at five years, despite standard chemoradiation treatment. At recurrence, systemic treatment options are limited of care not well defined, with inclusion in clinical trials being highly encouraged. So far, use immunotherapeutic strategies GBM has proved to significantly improve patients’ prognosis newly diagnosed GBM, nor recurrent setting. Probably this do unique immune environment central nervous system, which harbors several immunosuppressive/pro-tumorigenic factors, both soluble (e.g., TGF-β, IL-10, STAT3, prostaglandin E2, VEGF) cellular Tregs, M2 phenotype TAMs, MDSC). Here we review composition GBMs microenvironment, specifically focusing on function T cell compartment. Moreover, give hints therapeutic strategies, such as checkpoint blockade, vaccinations, adoptive therapy, that, interacting tumor-infiltrating lymphocytes, might target different ways tumor microenvironment potentiate activity therapies. The path be followed advancing research immunotherapy for relies twofold strategy: testing combinatorial treatments, aiming restore active anti-tumor responses, tackling immunosuppression, additionally, designing more phase 0 window opportunity solid translational analyses gain deeper insight into on-treatment shaping microenvironment.
Language: Английский
Citations
5